Healthy Growth across all verticals in FY'22 slide image

Healthy Growth across all verticals in FY'22

Strong In-House API Development SOLID TUMOR ANASTROZOLE AXITINIB BICALUTAMIDE DOCETAXEL TRIHYDRATE ENZALUTAMIDE ERLOTINIB HYDROCHLORIDE FULVESTRANT GEFITINIB LAPATINIB LENVATINIB METHOTREXATE NINTEDANIB PAZOPANIB PEMETREXED SORAFENIB SUNITINIB TEMOZOLOMIDE IRINOTICAN AFATINIB CABOZANTINIB HEMATOLOGY AZACITIDINE AZACITIDINE- ORAL BENDAMUSTINE BORTEZOMIB SUPPORTIVE APREPITANT FOSAPREPITANT ZOLEDRONIC ACID DASATINIB HYDROXYUREA IMATINIB LENALIDOMIDE PLERIXAFOR CARFILZOMIB API Under Development PALBOCICLIB ERIBULIN CERITINIB ELTROMBOPAG RUCAPARIB BETA Brugs DRUGS LTD.
View entire presentation